Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs H-101 (Primary)
Indications Cervical cancer; Endometrial cancer; Gynaecological cancer; Ovarian cancer; Uterine cancer; Vulvovaginal cancer
Focus Therapeutic Use

04 Jun 2024 Results (n=116) assessing efficacy of recombinant human adenovirus type 5 (H101) intra-tumor therapy in persistent/recurrent/metastatic gynecological cancer and the exploration of changes in tumor microenvironment presented at the 60th Annual Meeting of the American Society of Clinical Oncology
02 Jun 2024 Planned End Date changed from 30 Dec 2023 to 30 Mar 2025.
24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com